Loading clinical trials...
Loading clinical trials...
This is a long-term open-label safety extension to the Phase 2a study of inhaled QCC374 in adult patients with PAH. This study provides the patients who completed the QCC374X2201 study with the option...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Novartis Pharmaceuticals
NCT07218029 · Pulmonary Arterial Hypertension
NCT07120789 · Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), and more
NCT06649110 · Healthy Volunteers, Pulmonary Arterial Hypertension
NCT04778046 · Interstitial Lung Disease, COPD, and more
NCT06481852 · Pulmonary Arterial Hypertension
Novartis Investigative Site
Pittsburgh, Pennsylvania
Novartis Investigative Site
Dresden
Novartis Investigative Site
Heidelberg
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions